uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
15.38
+1.13 (7.93%)
At close: Jul 23, 2025, 4:00 PM
15.59
+0.21 (1.34%)
After-hours: Jul 23, 2025, 7:59 PM EDT
uniQure Revenue
uniQure had revenue of $1.57M in the quarter ending March 31, 2025, a decrease of -81.53%. This brings the company's revenue in the last twelve months to $20.20M, up 6.30% year-over-year. In the year 2024, uniQure had annual revenue of $27.12M with 71.17% growth.
Revenue (ttm)
$20.20M
Revenue Growth
+6.30%
P/S Ratio
37.94
Revenue / Employee
$96,656
Employees
209
Market Cap
842.03M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
QURE News
- 1 day ago - uniQure to Announce Second Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer - GlobeNewsWire
- 7 weeks ago - uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease - GlobeNewsWire
- 2 months ago - uniQure's AMT-130 Gene Therapy Warrants An Upgrade - Seeking Alpha
- 2 months ago - Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair - GlobeNewsWire
- 2 months ago - uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress - GlobeNewsWire
- 2 months ago - uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data - Seeking Alpha